Speak with other shareholders about: (OTC: LDPH), (OTCBB: CWLC) and (NASDAQ: SNSS) .

Are you looking to speak with other investors about your favorite stock? Stockwire.com, ranked in the top 5,000 websites in the United States by Alexa.com/Amazon.com, has created one of the finest chat programs available for investors. Now you can chat real-time with like-minded individuals about your favorite stock. Visit Stockwire.com and click the "Chat Now" button at the top.

Have you ever watched a STOCKUMENTARY? Click the following link to view your first ever full length STOCKUMENTARY: http://www.stockwire.com/cdrom/streaming_flash_page.htm .

----------------------------------------------------------

Talk to other LDPH shareholders by clicking the following link: http://www.stockwire.com/talkback?LDPH .

To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=LDPH .

London & Pacific Hea (OTC: LDPH)

London & Pacific Healthcare, Inc. Signs Long-Term Exclusive Agreement With NASD Broker Dealer Company Aligns With L&P Capital Advisors to Provide Broad Range of Healthcare Finance Services

June 5, 2007-- London & Pacific Healthcare, Inc. (OTC: LDPH) ("London & Pacific," the "Company"), a corporate finance and development company, today announced its long-term agreement with L&P Capital Advisors, LLC ("L&P Capital") to be the exclusive broker dealer for all of its transactions requiring investment banking services. This service contract will enable the Company to further access investment capital, build on revenue growth, streamline operations and enhance service offerings to its growing national and international client base. L&P Capital will work exclusively with the Company on all of its healthcare related finance transactions. This exclusive relationship with a Broker/Dealer positions the Company uniquely in the marketplace, providing additional bandwidth for deal origination and funding. L&P Capital recently secured its membership in the National Association of Securities Dealers (NASD). London & Pacific will begin transacting all of its securities business, with immediate effect, through L&P Capital, Member NASD.

"L&P Capital, which will locate its office contiguous to our El Segundo (Los Angeles) office, will enable London & Pacific to significantly broaden its service offerings to its clients. This arrangement provides each of our clients with the ability to seamlessly tap into a comprehensive range of capital sources to meet their specific needs," said Stuart Bruck, Executive Chairman of London & Pacific.

Eric J. Weissman, currently Managing Director of London & Pacific, has been appointed President of L&P Capital. Mr. Weissman will bring valuable experience in the areas of investment banking and public accounting, including a track record of successful healthcare mergers and acquisitions and other capital raising transactions in the healthcare sector.

About London & Pacific Healthcare, Inc.

London & Pacific Healthcare, Inc., with offices in Los Angeles and London, operates three synergistic operating divisions that capitalize on emerging growth opportunities in the global healthcare industry. City & Westminster Advisers Limited provides comprehensive strategic and financial advisory services to healthcare companies and organizations. HealthSPAC LLC, is a financial sponsor and incubator for Special Purpose Acquisition Companies (SPACs) in healthcare. Healthcare Fund Advisors LLC, provides specialized buy-side sourcing and analysis services to clients investing in the global healthcare sector. For additional information, please visit the corporate website at www.lphealthcare.com.

----------------------------------------------------------

Talk to other CWLC shareholders by clicking the following link: http://www.stockwire.com/talkback?CWLC .

To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=CWLC .

China Wireless Communications Inc. (OTCBB: CWLC)

China Wireless Communications, Inc. Contracts with Hyundai High-Tech Electronics Ltd. to Provide an Outsourced Network Management and Maintenance Solution

June 5, 2007-- China Wireless Communications, Inc., (OTCBB: CWLC), is pleased to announce it has been selected by Hyundai High-Tech Electronics, Ltd. to build the network for Hyundai's headquarters and manufacturing plant based in Tianjin, China. Frank Li, President of Tianjin Create Electronic Information Technology Co. LTD, a systems integration company and subsidiary of China Wireless Communications, has signed a contract with Hyundai High-Tech Electronics, Ltd. a subsidiary of the Korean based automobile manufacturer Hyundai AutoNet, to provide the outsourced engineering, management, maintenance, and computer equipment for the headquarters and manufacturing plant located in Tianjin, China.

About Hyundai High-Tech Electronics, Ltd.

Tianjin based Hyundai High-Tech Electronics, Ltd. is the headquarters for the company which provides electronic parts for Hyundai automobiles manufactured in China. The company also is a supplier of electronic products to other automobile manufacturers in China.

About China Wireless Communications, Inc.

China Wireless Communications, Inc., headquartered in Denver, CO, is an information technology company in North America and Asia. Our business plan is to provide both wireless and wired high-speed data and telecommunication connectivity for data and video over internet network systems to our customers.

----------------------------------------------------------

Talk to other SNSS shareholders by clicking the following link: http://www.stockwire.com/talkback?SNSS .

To view in-depth research, click the following link: http://www.stockwire.com/detailed/analysis.php?company=SNSS .

Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS)

Sunesis Pharmaceuticals Receives Preclinical Milestone Payment from SARcode Corporation

June 5, 2007-- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has earned a milestone payment from SARcode Corporation for progress made by SARcode in the preclinical development of a novel LFA-1 inhibitor candidate. The milestone payment, a $375,000 convertible note, increases Sunesis' potential ownership of SARcode and was triggered by SARcode's selection of an LFA-1 inhibitor development candidate and the commencement of GLP toxicology studies. SARcode is initially seeking to develop the small molecule LFA-1 candidate for T-cell mediated ophthalmic diseases.

"We congratulate SARcode on the rapid progress in this program and look forward to their continued success as this candidate advances toward the clinic," said Daniel N. Swisher, Sunesis' Chief Executive Officer and President. "As we advance our internal clinical-stage oncology pipeline, we are pleased to be able to leverage Sunesis' promising research on small molecule inhibitors for conditions that fall outside of our development focus through out-licensing arrangements such as this one." In January of this year, Sunesis announced the out-licensing of worldwide rights to patents and know-how related to Sunesis' LFA-1 inhibitor program to SARcode in exchange for license fees, convertible notes, milestone payments as well as potential royalty payments. The next payable milestone, if earned, will be for the filing of an Investigational New Drug application. Sunesis had previously discontinued the LFA-1 inhibitor program, which is outside of the company's strategic focus on discovering and developing novel small molecule therapeutics to treat cancer.

About Sunesis Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

----------------------------------------------------------

As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.

As the saying goes...follow the money!

To see the complete Movers & Shakers Blog go to: http://www.stockwire.com .

About Stockwire: Stockwire is a company that is pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.

The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.

Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.

As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.

While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.

Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml

Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.

From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. Likewise, Stockwire.com is owned by Stockwire Research Group Inc. (SRGI). To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.

All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company on Stockwire.com is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.

We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.

While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .